


**ADVANCING GLOBAL EQUITABLE  
ACCESS TO VACCINES: INTELLECTUAL  
PROPERTY, TECHNOLOGY TRANSFER  
AND CONTRACTS**

Panel Discussion  
2 December 2022

**Comments by Julia Barnes-Weise**



# What Does GHIAA Do?



- We provide tools and resources to **support the formation of partnerships** that will **facilitate access** to critical medical products.
- Our goals are to:
  - Address the need for **greater transparency** of the agreement terms that have an impact on global health.
  - **Raise awareness** of the importance & relevance of agreement terms in translating access policies into meaningful & measurable impact.
  - Provide **advice and resources** for those seeking to understand and implement access policies in their agreements.
  - **Facilitate collaborative efforts** & open dialogue related to the development, negotiation and implementation of global health agreements.

# Why Do Contracts Matter?



- Contracts provide the legal framework that governs a partnership.
- The terms of a contract should clearly explain the rights and obligations of all parties in achieving the objectives of a partnership.
- Signature of a contract provides a confirmation that the parties have aligned expectations for the partnership.
- Without this written alignment, there is an increased risk of misunderstandings and failure to achieve the intended outcomes.
- The lifecycle of a medical product can involve many different contracts such as funding for product development, licensing of intellectual property rights and supply of a product to a purchasing organization.
- It is important to consider how the terms of one contract might affect a future contract, particularly if the final goal is to ensure equitable access to the product.

# GHIAA MAPGuide®



## What is it?

An **open access** tool containing **analysis of provisions** from global health agreements.


It is organized into **key issues** for developing & rapidly concluding global health agreements with the aim of enabling increased access to medical products.

## Why did we develop it?

The 2014 Ebola outbreak in West Africa exposed significant gaps in epidemic preparedness, including readiness to **rapidly conclude R&D collaboration** agreements.

Negotiations were hindered by a **lack of clarity on appropriate approaches** to key issues. We identified the need for a tool to help stakeholders assess the **range of options** available.

# Key Components of Equitable Access





[www.ghiaa.org](http://www.ghiaa.org)

[comms@ghiaa.org](mailto:comms@ghiaa.org)

[LinkedIn](#) [Twitter](#)

[Newsletter](#)